Salarius Pharmaceuticals Addresses Errors on S&P CapIQ Platform, Affirms Nasdaq Listing Under 'SLRX' Symbol
ByAinvest
Wednesday, Nov 19, 2025 2:45 pm ET1min read
SLRX--
Salarius Pharmaceuticals cites an error on S&P CapIQ platform, affirming its shares continue to trade on the Nasdaq Stock Market under the symbol "SLRX". The company completed a merger with Decoy Therapeutics and raised $8 million in an underwritten public offering. With pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding, Salarius is focused on advancing Decoy's pipeline of peptide conjugate therapeutics.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet